BAYERCROP · Basic Materials · Agricultural Inputs
Composite scorecard: 52/100 — Quality 65 · Momentum 19
| Share price | ₹4,260.90 |
| Market cap | ₹21,011 Cr |
| P/E ratio | 31.3 |
| P/B ratio | 6.7 |
| ROE | 24.1% |
| ROCE | 24.0% |
| Dividend yield | 2.68% |
| Book value | ₹695.07 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2025 | ₹5,314 Cr | ₹568 Cr | 11.5% |
| 2024 | ₹4,892 Cr | ₹740 Cr | 18.6% |
| 2023 | ₹4,945 Cr | ₹758 Cr | 17.4% |
| 2022 | ₹4,577 Cr | ₹645 Cr | 16.6% |
| 2021 | — | — | — |
Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and hybrid corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes row crop hybrid seeds. Fur